39 citations
,
November 2015 in “Pediatric Nephrology” Rituximab leads to longer remission and fewer side effects than cyclophosphamide.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
6 citations
,
January 2023 in “Medical Mycology Journal” Fosravuconazole effectively treated a woman's scalp infection without side effects.
September 2023 in “Journal of the American Academy of Dermatology” 2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
147 citations
,
October 2021 in “Cancer Communications” RC48 shows promise for treating certain advanced cancers, but more research is needed.
September 2025 in “International Journal of Pharmacy and Biomedical Engineering” Drug repurposing finds new uses for existing drugs, speeding up treatment availability and reducing costs.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
August 2019 in “Journal of The American Academy of Dermatology” RV3466F lotion significantly reduces hair loss and improves acute telogen effluvium.
14 citations
,
March 2019 in “European journal of pharmaceutics and biopharmaceutics” Proretinal nanoparticles improve skin absorption and reduce irritation of topical retinoids.
January 2024 in “Wiadomości Lekarskie” New vaccine technologies are improving global health by making vaccines more effective and long-lasting.
1 citations
,
June 2025 in “Journal of Allergy and Clinical Immunology Global” A young boy with Netherton syndrome improved significantly using IVIG, dupilumab, and dietary changes.
56 citations
,
January 2023 in “Genes & Diseases” Repurposing existing drugs and using micronutrients may effectively target cancer stem cells and improve cancer treatment.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
3 citations
,
June 1987 in “British Journal of Dermatology” Nifedipine may help treat perniosis, improving symptoms and clearing lesions for some patients.
December 2013 in “Urology reports (St - Petersburg)” Sonirid Duo effectively treats benign prostatic hyperplasia.
April 2026 in “The Open Biotechnology Journal” Resveratrol shows health benefits but faces challenges in effectiveness and regulation.
14 citations
,
November 2024 in “Pharmaceuticals” Spanlastic nano-vesicles improve famotidine's effectiveness and absorption.
35 citations
,
October 2004 in “Biology of Reproduction” PNU157706 reduced rat sperm movement and fertility without affecting offspring health.
170 citations
,
September 2020 in “Viruses” Drug repositioning offers a cost-effective, lower-risk way to treat diseases and pandemics like COVID-19.
February 2025 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair and improve psoriasis.
9 citations
,
November 2018 in “Journal of cosmetic dermatology” Orobanche rapum extract rejuvenates skin and protects skin bacteria, leading to healthier skin.
April 2023 in “Journal of Investigative Dermatology” RNase L suppresses regeneration in mammals.
80 citations
,
January 1995 in “The Nephron journals/Nephron journals” The treatment was effective for lupus nephritis with manageable side effects.
34 citations
,
July 2011 in “International journal of pharmaceutics” Ion-paired risedronate significantly increases skin penetration without irritation compared to risedronate alone.
The new delivery system makes retinol and niacinamide more stable and effective for anti-aging and skin-brightening.
21 citations
,
January 2022 in “Biomaterials Science” RNA delivery is best for in-body use, while RNP delivery is good for outside-body use. Both methods are expected to greatly impact future treatments.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
47 citations
,
October 1989 in “European Journal of Pediatrics” Two siblings stayed rickets-free for 14 years after stopping treatment.